No Data
No Data
Koyuan Pharmaceuticals (301281.SZ) is planning to acquire the controlling stake of Hongjitang and raise supporting funds. Trading will be suspended from October 8th.
GeLongHui October 8th | KeYuan Pharmaceutical (301281.SZ) announced that the company plans to purchase the controlling stake of Shandong Hongji Tang Pharmaceutical Group Co., Ltd. (referred to as "HongJiTang") through the issuance of A-share shares and other methods, and raise supporting funds. This transaction is still in the planning stage, and the company is currently in contact with the shareholders of the target company. The final transaction will be subject to the negotiations between the company and the shareholders of the target company. The main transaction parties preliminarily identified for the issuance of shares to purchase assets include Lino Investment Holdings Group Co., Ltd. (referred to as "Lino Investment"), Lino Group Co., Ltd. (referred to as "Lino".
Private Companies in Shandong Keyuan Pharmaceutical Co., Ltd. (SZSE:301281) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 18% Last Week
Hengrui Pharmaceuticals (301281.SZ): 6.3 million shares of restricted shares will be lifted on October 8th.
Koyuan Pharmaceuticals (301281.SZ) announced on September 25 that the number of shareholders applying for the removal of restricted stocks this time totaled 1, with the number of restricted shares being 6.3 million shares, accounting for 5.8177% of the total share capital of the company. The restriction period is 18 months from the date of the company's initial public offering and listing. The unrestricted shares will be listed for trading on October 8, 2024 (Tuesday).
Kewei Pharmaceutical (301281.SZ) 6.3 million restricted shares will be listed for trading on October 8th.
Kangyuan Pharmaceutical (301281.SZ) announced that the number of shares to be released this time before the initial public offering has been lifted...
Shandong Keyuan Pharmaceutical: Summary of Half-Year Report in 2024.
Shandong Keyuan Pharmaceutical: Half-year report for the year 2024.
No Data
No Data